Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 4,637 matching trials from the live ClinicalTrials.gov search.

Filters: Los Angeles, California Clear all

Conditions: Coronary Artery Disease
Interventions: Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin); Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 73
States / cities: Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 58 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole, Dapsone, Leucovorin calcium; Drug
Lead sponsor: U.S. Bioscience; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 13 Months to 30 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 109
States / cities: Birmingham, Alabama • Phoenix, Arizona • Downey, California + 91 more

Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 21 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: PF-06821497, Placebo, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 39
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 25 more

Conditions: Niemann-Pick Type C Disease
Interventions: Adrabetadex; Drug
Lead sponsor: Mandos LLC; Industry
Eligibility: 4 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 13 more

Conditions: SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions: Somapacitan, Norditropin®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more

Conditions: Epilepsy
Interventions: Activa™ PC and Percept™ PC Neurostimulation Systems; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more

Conditions: Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Emotion Regulation
Interventions: Social regulation, Cognitive regulation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus Type 2, Childhood-Onset
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 8 Years to 15 Years
Enrollment: 3,600 participants
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Infant Immunity Response and Immunoglobulin Diversity
Interventions: blood sample/ stool sample; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Stage III Colon Cancer
Interventions: Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month; Device · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1045
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 730 more

Conditions: Weight Reduction, Obesity, Weight Management
Interventions: Herbalife Meal Replacements; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Interventions: Biomarker Analysis, Blood Product Collection; Other · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 412
States / cities: Gilbert, Arizona • Kingman, Arizona • Tucson, Arizona + 261 more

Conditions: Non-Small Cell Lung Cancer
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 17
States / cities: Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 14 more

Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions: Axitinib, Nivolumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 266
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 168 more

Conditions: Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement, Piperine Extract (Standardized), Placebo Administration, Questionnaire Administration; Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Moderate-severe Pain
Interventions: Ages 7-11, ages 12-17; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Irvine, California • Los Angeles, California • Orange, California + 5 more

Conditions: Pain, Appetite Loss, Abuse, Drug
Interventions: Placebo, Low CBG, High CBG, Low THC, High THC; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Neoplasm
Interventions: Stereotactic Radiotherapy, Anatomic Pulmonary Resection; Radiation · Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2034
U.S. locations: 17
States / cities: Long Beach, California • West Los Angeles, California • Bay Pines, Florida + 14 more

Conditions: Growth Hormone Deficiency in Children
Interventions: Somapacitan, Norditropin®; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 11 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more

Conditions: HIV Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 28
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Idiopathic Short Stature
Interventions: Not listed
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 33 more

Search by objective public record fields.

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

Longitudinal Study of Mitochondrial Hepatopathies

Social Facilitation of Emotion Regulation in Adolescence

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

Infant Immunity Comparison of Breastfed and Bottlefed Infants

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial

A Study of miRNA 371 in Patients With Germ Cell Tumors

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

A Study to Assess Growth in Children With Idiopathic Short Stature